EcoDrugPlus

Methionine Aminopeptidase 2-Like

Ensembl ID : ENSPNAG00000029913
Gene Symbol: LOC108428789
4 Cross references
220 Possible Orthologues:

Methyltransferase-Like Protein 2-A

Ensembl ID : ENSPNAG00000013832
Gene Symbol: LOC108413591
3 Cross references
201 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSPNAG00000021720
Gene Symbol: LOC108441162
2 Cross references
203 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSPNAG00000013493
Gene Symbol: LOC108439131
2 Cross references
152 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSPNAG00000020691
Gene Symbol: MAPK1
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSPNAG00000022031
Gene Symbol: LOC108411041
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSPNAG00000020204
Gene Symbol: LOC108415313
3 Cross references
87 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSPNAG00000020224
Gene Symbol: LOC108442323
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSPNAG00000018072
Gene Symbol: MAPK14
3 Cross references
159 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a-Like

Ensembl ID : ENSPNAG00000011949
Gene Symbol: LOC108436315
3 Cross references
83 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSPNAG00000023412
Gene Symbol: LOC108437314
3 Cross references
225 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSPNAG00000007719
Gene Symbol: LOC108443371
3 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).